Understanding the Market | KINTOR PHARMA-B rose over 8% in the morning as the company is actively advancing the registration application preparation for KT-939
KINTOR PHARMA-B's stock price rose more than 8% in the morning, reaching HKD 2.42, with a transaction volume of HKD 9.6388 million. The company is actively advancing the registration application for the new efficient tyrosinase inhibitor KT-939, planning to submit the application to the drug regulatory authority in the third quarter of next year. KT-939 has completed multiple safety and toxicology assessments, performing well, and is expected to become the first independently developed and approved new raw material for whitening cosmetic products in China
According to Zhitong Finance APP, KINTOR PHARMA-B (09939) rose more than 8% in the morning, and as of the time of publication, it increased by 8.52%, trading at HKD 2.42, with a transaction volume of HKD 9.6388 million.
On the news front, on September 9, KINTOR PHARMA-B announced that the long-term safety trial of its independently developed novel and highly efficient tyrosinase inhibitor KT-939 for inhibiting melanin production has recently completed the enrollment of all 130 subjects. KT-939 can precisely target tyrosinase, effectively blocking the oxidation process of tyrosine, thereby effectively curbing melanin production, while also possessing antioxidant and anti-inflammatory properties, demonstrating outstanding advantages in the efficacy and safety of cosmetics.
As of the date of this announcement, KT-939 has completed multiple safety and toxicology assessment trials as well as a 28-day continuous topical efficacy trial in humans. The trial results indicate that KT-939 performs well in both efficacy and safety. Based on the previous comparison of the efficacy and safety of KT-939 with commonly used whitening ingredients such as Thiamidol and 377, the company is actively advancing the registration application preparation for KT-939, planning to officially submit the registration application to the National Medical Products Administration of China in the third quarter of next year.
The tyrosinase inhibitor Thiamidol, which targets melanin production through the same mechanism, was approved for registration by the National Medical Products Administration of China in November 2024, becoming the first and currently the only newly approved whitening cosmetic ingredient since the implementation of the "Cosmetics Supervision and Administration Regulations" in 2021, and the second whitening cosmetic ingredient approved for registration in China after 377, 12 years later. KT-939 is expected to become the first independently developed and approved whitening cosmetic ingredient in China, achieving a "zero breakthrough" in the field of fully independent intellectual property rights, providing new options for the spot removal and whitening cosmetic market in China and globally
